STOCK TITAN
  1. Home
  2. News
  3. ALVO

Alvotech Stock Price, News & Analysis

ALVO Nasdaq

Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.

Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.

Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.

Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.

Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.

News

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) and Advanz Pharma announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for AVT06, their proposed biosimilar to Eylea (aflibercept 2 mg). The biosimilar is intended to treat various eye disorders including wet age-related macular degeneration, visual impairment due to macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation. Alvotech will handle development and commercial supply, while Advanz Pharma will manage registration and exclusive commercialization in most European countries. Notably, Eylea's global sales reached approximately $9 billion in 2024, with one-third coming from Europe. A confirmatory clinical study completed in January 2024 demonstrated therapeutic equivalence between AVT06 and Eylea. Additionally, Alvotech is developing AVT29, a proposed biosimilar to the higher-dose Eylea HD (aflibercept 8 mg).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
-
News

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has successfully completed a private placement of shares and Swedish Depositary Receipts (SDRs) announced on June 4, 2025. The placement attracted approximately 40 institutional investors, with 60% of demand coming from Sweden, Norway, and UK investors, and 30% from US-based funds. Notably, over 80% of the allocated shares and SDRs were purchased by new investors. The placement involved the transfer of 7.5 million treasury shares from Alvotech's subsidiary Alvotech Manco ehf. According to CEO Róbert Wessman, this placement will diversify and strengthen Alvotech's shareholder base while increasing the free float of SDRs on Nasdaq Stockholm, where approximately 8.5 million SDRs are currently trading.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
private placement
-
News

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on June 11 at 8:00 am EDT. The session will be webcast live and accessible to the public through Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
News

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Chief Strategy Officer Dr. Balaji Prasad will participate in a fireside chat on June 11, 2025, at 8:00 am EDT. The session will be publicly accessible via webcast through Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) and Dr. Reddy's Laboratories have announced a strategic collaboration to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab), a major cancer treatment drug. The partnership leverages both companies' biosimilar expertise to accelerate development and expand global reach. Under the agreement, both parties will share development costs, manufacturing responsibilities, and commercialization rights globally. This collaboration targets a significant market opportunity, as Keytruda generated US$29.5 billion in worldwide sales in 2024. The partnership aims to increase the availability of cost-effective biologic medications for cancer treatment worldwide, with oncology being a key focus area for both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
News

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has successfully completed a private placement of 7.5 million shares, comprising 5,833,500 SDRs and 1,666,500 ordinary shares, priced at SEK 100.00 per SDR and ISK 1320.83 per ordinary share. The placement raised SEK 750 million in gross proceeds, with strong interest primarily from Swedish and international investors outside Iceland. The funds will be used to scale up R&D efforts, particularly in Sweden following the Xbrane R&D operations acquisition, capitalize on growth opportunities, and for general corporate purposes. Settlement is expected around June 10, 2025. The company and its executives have agreed to lock-up periods of 180 days, while major shareholders have committed to 90-day lock-up periods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
private placement
News

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announces plans to conduct a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares, targeting Swedish and international institutional investors through an accelerated bookbuilding process. The offering will utilize existing treasury shares, with DNB Carnegie, Citi, SEB, and ACRO serving as Joint Bookrunners. The placement aims to strengthen Alvotech's shareholder base, particularly in Sweden following its recent Nasdaq Stockholm listing. Proceeds will fund R&D activities expansion, especially in Sweden after acquiring Xbrane's R&D operations. The company and insiders have agreed to lock-up periods ranging from 90-180 days post-settlement. Major shareholders Aztiq Pharma, Alvogen Lux, and Celtic Holdings II are maintaining their positions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
private placement
-
News

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) has completed its acquisition of Xbrane Biopharma AB's R&D organization in Sweden and its biosimilar candidate to Cimzia® (certolizumab pegol). The transaction, valued at approximately SEK 275 million (US$28.9 million), includes a cash payment of SEK 102.2 million, convertible debt assumption of SEK 152.75 million, and accounts payable assumption of SEK 20 million related to the biosimilar candidate. The acquisition, which received approval from Xbrane's Extraordinary General Meeting on April 14, 2025, aims to expand Alvotech's development capabilities and establish a strong presence in the Swedish life science sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
acquisition
-
News

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

Rhea-AI Summary
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025 in New York. The event will take place from June 3-5, 2025, where the company's management team will conduct one-on-one meetings. Dr. Balaji Prasad, Chief Strategy Officer, will deliver a business update presentation on June 5, 2025, from 10:30-11:00 am EDT. The presentation will be accessible via live video webcast on Alvotech's investor relations website, with a replay available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
News

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Rhea-AI Summary
Alvotech (NASDAQ: ALVO) and Advanz Pharma have expanded their strategic partnership to include three additional biosimilar candidates in Europe. The new agreement covers biosimilars to Ilaris® (canakinumab) for inflammatory diseases, Kesimpta® (ofatumumab) for multiple sclerosis, and an undisclosed candidate. The deal includes development and commercial milestones worth up to $180 million, plus revenue sharing. This expansion builds on their 2023 partnership covering eight other biosimilars. Alvotech will handle development and supply, while Advanz Pharma will manage registration and commercialization across the European Economic Area, UK, and Switzerland. The total addressable market for all partnered biosimilars in the covered regions is estimated at $13.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
partnership

FAQ

What is the current stock price of Alvotech (ALVO)?

The current stock price of Alvotech (ALVO) is $3.33 as of March 23, 2026.

What is the market cap of Alvotech (ALVO)?

The market cap of Alvotech (ALVO) is approximately 1.1B.

ALVO Rankings

#2686 Ranked by Market Cap
N/A Ranked by Dividends

ALVO Stock Data

1.10B
117.87M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Luxembourg
Luxembourg

ALVO RSS Feed